Artículos de Revisión |
|
||
 Página
principal |
|||
| 2012 | Enlaces al artículo: | ||
|
Cannabidiol for neurodegenerative disorders:
important new clinical applications for this phytocannabinoid? Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee RG, Mechoulam R, Martínez-Orgado J British Journal of Clinical Pharmacology (en prensa) |
|||
|
Cannabinoid drugs for neurological diseases: what is behind? |
 |
||
|
Cannabinoids: Novel medicines for the treatment of Huntington´s disease Sagredo O, Pazos MR, Valdeolivas S, Fernández-Ruiz J Recent Patents on CNS Drug Discovery 7, 41-48 |
|
||
| 2011 | |||
|
Prospects for cannabinoid therapies in basal ganglia disorders |
|
||
| 2010 | |||
|
The endocannabinoid system as a target for the
treatment of neuronal damage Fernández-Ruiz J, García C, Sagredo O, Gómez M, de Lago E Expert Opinion on Therapeutic Targets 14, 387-404 |
|
||
|
Cannabinoid-dopamine interaction in the pathophysiology and treatment of
CNS disorders Fernández-Ruiz, J, Hernandez ML, Ramos JA CNS Neuroscience & Therapeutics 16, 72-91 |
|
||
| 2009 | |||
|
Cannabinoids and Parkinson´s disease García-Arencibia M, García C, Fernández-Ruiz J. CNS Neurol Disord Drug Targets 8, 432-439 |
|
||
|
Cannabinoids, multiple sclerosis and neuroprotection de Lago E, Gómez-Ruiz M, Moreno-Martet M, Fernández-Ruiz J Expert Review of Clinical Pharmacology 2, 645-660 |
|||
|
The endocannabinoid system as a target for treatment of motor dysfunction Fernández-Ruiz J British Journal of Pharmacology 156, 1029-1040 |
|
||
|
The endocannabinoid system in neuropathological states Orgado JM, Fernández-Ruiz J, Romero J International Review of Psychiatry 21, 172-180 |
|
||
| 2008 | |||
|
Cannabinoid signalling system: Does it play a function in cell proliferation and migration, neuritic elongation and guidance and synaptogenesis during brain ontogenesis? Gómez M, Hernández ML, Fernández-Ruiz J Cell Adhesion & Migration 2, 246-248 |
|
||
|
The endocannabinoid system in Huntington´s disease. Pazos MR, Sagredo O, Fernández-Ruiz J.. Current Pharmacological Design 14, 2317-2325 |
|
||
|
Role of CB2 receptors in neuroprotective effects of cannabinoids. Fernández-Ruiz J, Pazos MR, García-Arencibia M, Sagredo O, Ramos JA. Molecular and Cellular Endocrinology 286S, S91-S96 |
|
||
| 2007 | |||
|
An overview on the biochemistry of the
cannabinoid system Gómez-Ruiz M, Hernández ML, de Miguel R, Ramos JA Molecular Neurobiology 36, 3-14 |
|
||
|
Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Fernández-Ruiz J, Romero J, Velasco G, Tolón RM, Ramos JA, Guzmán M. Trends in Pharmacological Sciences 28, 39-45 |
|
||
|
|
Cannabinoids and neuroprotection in motor-related disorders. de Lago E, Fernández-Ruiz J. CNS Neurol Disord Drug Targets 6, 377-387 |
|
|
|
Cannabinoids and neuroprotection in basal ganglia disorders. Sagredo O, García-Arencibia M, de Lago E, Finetti S, Decio A, Fernández-Ruiz J. Molecular Neurobiology 36, 82-91 |
|
||
| 2006 | |||
|
An overview of Parkinson's disease and the
cannabinoid system and possible benefits of cannabinoid-based treatments. Lastres-Becker I, Fernandez-Ruiz J. Curr Med Chem.13, 3705-3718 |
|
||
| 2005 |
|
||
|
Therapeutic potential of the endocannabinoid system in the brain. Ramos JA, Gonzalez S, Sagredo O, Gomez-Ruiz M, Fernandez-Ruiz J Mini Rev Med Chem. 5, 609-617 |
|
||
|
Cannabinoid tolerance and dependence: a review of studies in laboratory animals Gonzalez S, Cebeira M, Fernandez-Ruiz J. Pharmacol Biochem Behav. 81, 300-318 |
|